shutterstock_1773559100_isabelle_ohara

Isabelle OHara / Shutterstock.com

25 April 2022GenericsAlex Baldwin

Aetna gets antitrust suit moved back to state court

American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead loses bid to quash parallel antitrust HIV lawsuit

31 March 2022 Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Dr Reddy’s hits Amarin with antitrust suit over Vascepa

29 April 2021 Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.

More on this story

Gilead loses bid to quash parallel antitrust HIV lawsuit

31 March 2022 Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Dr Reddy’s hits Amarin with antitrust suit over Vascepa

29 April 2021 Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.

More on this story

Gilead loses bid to quash parallel antitrust HIV lawsuit

31 March 2022 Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Dr Reddy’s hits Amarin with antitrust suit over Vascepa

29 April 2021 Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York